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Abstract Influenza virus is a major cause of disease
worldwide. The accurate detection and further subtyping of
influenza A viruses are important for epidemiologic surveil-
lance, and subsequent comprehensive characterization of
circulating influenza viruses is essential for the selection of
an optimal vaccine composition. ResPlex III is a new
multiplex reverse transcriptase polymerase chain reaction
(RT-PCR)-based method for detecting, typing, and subtyping
influenza virus in clinical specimens. The ResPlex III assay
was compared with other methods with respect to sensitivity
and accuracy, using 450 clinical specimens obtained from
subjects throughout Germany during the 2006–2007 influenza
season. Samples were analyzed for the presence of influenza
virus in Madin-Darby canine kidney (MDCK) cells by rapid
cell culture using peroxidase staining and conventional cell
culture confirmed by hemagglutination inhibition assay, a
rapid diagnostic assay (Directigen Flu A+B test; BD
Diagnostic Systems, Heidelberg, Germany), in-house real-
time RT-PCR (RRT-PCR), and ResPlex III (Qiagen, Hilden,
Germany). ResPlex III had the highest sensitivity for detecting
influenza virus in clinical specimens, followed by in-house
RRT-PCR (96% compared with ResPlex III). Conventional
cell culture in MDCK cells, rapid culture, and quick test
assays were substantially less sensitive (55%, 72%, and 39%,
respectively). Virus subtyping results were identical using
ResPlex III and the standard virological subtyping
method, hemagglutination inhibition. ResPlex III is a
quick, accurate, and sensitive assay for detecting and
typing influenza A and B viruses and subtyping
influenza A viruses in clinical specimens, and might
be considered for a supplemental role in worldwide
seasonal and pandemic influenza surveillance.
Background
Seasonal influenza is responsible for a high disease burden
worldwide. Up to 5–15% of the global population is
affected by influenza annually [21]. Influenza epidemics
result in an average of 294,000 hospitalizations and 36,000
deaths each year in the US alone [15, 16]. The best way to
prevent influenza is yearly vaccination with seasonal
vaccines that are designed to include antigens from three
strains recommended by the World Health Organization
(WHO). Virological surveillance to identify predominant
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circulating influenza virus strains is essential to determine the
optimal strains as seasonal influenza vaccine components, and
to provide information about the possible emergence of new
virus strains with pandemic potential [6]. If vaccine strains do
not closely match the strains causing disease in a given year,
vaccine efficacy may be reduced, with a potentially
significant impact on public health [2].
Reverse transcriptase polymerase chain reaction (RT-
PCR)-based methods have replaced viral culture as the
reference standard for the detection of influenza viruses
[10, 12]. Results are obtained in 2–4 h [3] and, compared to
viral culture methods, the specificity is improved and the
sensitivity is 2–13% higher [22]. Due to its speed,
sensitivity, and specificity, real-time RT-PCR (RRT-PCR)
has been recognized as an attractive method of detecting
influenza viruses. However singleplex, real-time, one-step
RT-PCR cannot distinguish type A and B viruses or allow
further subtyping of type A viruses. Thus, different assays
have to be used or combined into multiplex PCR assays.
New technologies that provide a quicker method of typing
and subtyping could enhance global surveillance programs,
and more rapid identification of potential pandemic strains
would allow more time to prepare for severe outbreaks of
disease. These new technologies would need to be at least
as sensitive and accurate as existing methods to ensure the
continued precision of global surveillance programs. There-
fore, the new ResPlex III assay, which detects HA/NA
subtypes (i.e., H1 seasonal, H2, H3, H5, H7, H9, N1, and
N2) and two influenza A or B generic targets of the non-
structural protein (NS) gene, was compared with current
diagnostic assays and conventional subtyping by using
specific immune sera. Molecular assays are valuable tools
for the rapid detection, typing, and subtyping of influenza
viruses. However, global influenza surveillance also
requires the isolation of virus in culture to allow for a
comprehensive analysis of the antigenic profile of circulat-




The aim of this study was to compare the ResPlex III assay
with other methods with respect to sensitivity and accuracy,
using 450 clinical specimens obtained from subjects through-
out Germany during the 2006–2007 influenza season.
Ethical standards
The study was carried out in compliance with the Helsinki
Declaration. None of the samples were collected for study
purposes. All samples were tested anonymously. Ethical
approval was not required.
Study collection
Throat or nasal swabs were obtained from 450 outpatients
with acute respiratory symptoms during the 2006–2007
influenza season by office-based physicians, mainly pedia-
tricians and general practitioners in the southern region of
Germany. Samples were collected during calendar weeks 4
through 14 of 2007 and stored in virus transport media for
routine diagnostics.
Study regime
Rapid test, conventional, and rapid cell culture with
adherent Madin-Darby canine kidney (MDCK) cells,
nucleic acid extraction, and RT-PCR were performed at
the Laboratory Prof. Enders & Partner, Stuttgart,
Germany. Aliquots of the extracted nucleic acid were
sent to Novartis Vaccines & Diagnostics GmbH for
ResPlex III testing. Conventional cell culture isolates
were submitted to the National Influenza Reference
Center for Influenza for typing/subtyping by hemagglu-
tination inhibition (HI). In addition, RRT-PCR-negative
but ResPlex III-positive clinical specimens were used for
the isolation of influenza viruses in MDCK33016PF
suspension culture developed by Novartis Vaccines &
Diagnostics GmbH [9].
BD Directigen Flu A+B (rapid test)
The BD Directigen Flu A+B is a rapid membrane enzyme
immunoassay, carried out with fresh clinical specimens accord-
ing to the manufacturer’s instructions (Becton Dickinson,
Sparks, MD).
Conventional cell culture
MDCK cells were grown in 3-mL flat Nunclon tubes
(Nunc, Langenselbold, Germany) in Eagle’s Minimal
Essential Medium (EMEM) containing 10% fetal bovine
serum (FBS). Prior to infection, the medium was replaced
with 2 mL of maintenance medium without FBS containing
tolylsulfonyl phenylalanyl chloromethyl ketone (TPCK)
trypsin (2 μg/mL). Cell culture tubes were inoculated with
0.2 mL of samples and incubated at 37°C. After 24 h, the
medium was replaced by 2 mL of maintenance medium
without FBS containing TPCK trypsin (2 μg/mL). The
tubes were checked daily for 7 to 10 days for cytopathic
effects (CPEs). After 7 to 10 days, the tubes were screened
by hemagglutination assay for the agglutination of guinea
pig erythrocytes (Charles River Laboratories, Sulzfeld,
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Germany) in the tissue culture supernatant to confirm
influenza virus replication.
Hemagglutination assays (adherent MDCK)
Hemagglutination assays were performed in microtiter U-
bottom plates with 25 μL of culture supernatant, 25 μL of
dextrose-gelatin-veronal (DGV) buffer, and 25 μL of washed
0.5% guinea pig erythrocytes (Charles River Laboratories,
Sulzfeld, Germany), suspended in DGV buffer. The plates
were incubated at room temperature for approximately 1 h.
HI assays
The HI procedure for subtyping influenza virus isolates has
been described previously [4]. Briefly, specific antisera raised
in ferrets were treated with receptor-destroying enzyme. HI
assays were performed using 4 hemagglutination units of
virus and 0.75% (vol/vol) guinea pig erythrocytes.
Rapid culture
The rapid culture technique was performed as described
previously [14]. MDCK cells were seeded in 96-well
microtiter plates in antibiotic-free EMEM containing 10%
FBS and incubated at 37°C for 1–3 days before testing. For
the detection of influenza A and B viruses in clinical
specimens, two wells were each inoculated with 100 μL of
sample after removing the medium. Plates were centrifuged
at 1,200×g for 30 min. The supernatant was then removed
and 200 μL of FBS-free medium containing TPCK trypsin
(2 μg/mL) were added. Plates were incubated in a moist
chamber at 37°C for 16–18 h under 5% CO2. Subsequently,
the cells were fixed for 10 min with ice-cold acetone/
methanol (40:60), then blocked with 1% bovine serum
albumin (BSA) in phosphate buffered saline (PBS) for
30 min, and incubated at 37°C for 30 min with monoclonal
antibodies produced in mice against influenza A or B
(Chemicon, Temecula, CA) diluted 1:100 in blocking
buffer (1% BSA in PBS). After washing three times with
PBS, the plates were incubated with a secondary horseradish
peroxidase-labeled antibody (DAKO, Glostrup, Denmark) at
a dilution of 1:500 in blocking buffer. The washing step was
repeated. Influenza-positive cells were stained using the
substrate 3-amino-9-ethylcarbazole (AEC) (Sigma, St. Louis,
MO) and counted microscopically.
MDCK 33016PF suspension culture
MDCK 33016PF, where PF indicates “protein free” and
33016 is the clone number, is a proprietary cell line that was
generated by Novartis [9]. The MDCK 33016PF cells from
Novartis’ working seed stocks were cultivated in 500-mL
spinner flasks (Wheaton) in CDM medium (MDCK 33016
CDM, Lonza) and passaged in 3–4-day intervals. During
those 3–4 days, the cells grew from an initial seeding density
of 1×105 cells/mL to densities between 1.0 and 1.5×106
cells/mL. For infections, 4.5 mL of cells were seeded in
50-mL filter tubes (TPP, Trasadingen, Switzerland) at a
cell density of 0.8 to 1.2×106 cells/mL in infection
medium, consisting of 70% MDCK 33016 PFM medium
(Gibco Invitrogen) and 30% MDCK 33016 CDM supple-
mented with 0.5% of a penicillin/streptomycin solution
(Sigma) and 900 IU/mL trypsin. To obtain a total culture
volume of 5 mL, the added inoculum clinical (stored at 2–
8°C) or virus sample was diluted in 0.5 mL of infection
medium and was prediluted by several log10 steps, starting
with a dilution of at least 1:5. Inoculated cultures were
then incubated at 33°C for 3 days in a 5% CO2 atmosphere
in an ISF-1-W shaker incubator (Kühner, Birsfelden,
Switzerland). For virus harvests, the cells were separated
by centrifugation (800–1,000×g for 10 min) and the
supernatant was recovered. Unless used freshly (e.g., for
hemagglutination tests and subsequent passaging), ali-
quots of the supernatant were frozen at ≤−60°C.
Hemagglutination assays (MDCK 33016PF)
Hemagglutination (HA) testing was done with harvested
material to define the starting material for the next passage.
HA testing was performed in U-bottom microwell plates
(Greiner Bio-One) using 100 μL of a serial log2 dilution in
PBS (pH 7.0) of the test samples and 100 μL of chicken or
guinea pig red blood cells (0.5% in PBS, pH 7.0). The
results were read after 60 min (chicken erythrocytes) or
120 min (guinea pig erythrocytes) incubation at ambient
temperature within a temperature range of 19–25°C. Two
different kinds of red blood cells were used, since H3N2
influenza strains did not react with chicken red blood cells.
Material from the highest log10 inoculum dilution, which
showed a clearly positive HA reaction after the previous
passage, was used for the following passage.
Automated nucleic acid isolation
Viral RNA was prepared from up to 32 samples in parallel
with the automated MagNA Pure instrument by using the
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche
Diagnostics GmbH, Mannheim, Germany). Briefly, the input
sample volume was 200 μL and nucleic acids were eluted in a
volume of 50 μL. Purified RNAwas stored at −20°C.
RT-PCR
The duplex RRT-PCR was done using the LightCycler
system. Amplification was performed in a 20-μL reaction
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volume consisting of 10 μL of kit-supplied QuantiTect
Probe Master Mix (Qiagen, Hilden, Germany), 0.5 μM of
each primer, 0.18 μM of probe, 0.2 μL of kit-supplied
QuantiTect RT mix, and 6.8 μL of purified RNA. Primers
and the two single probes were described previously [19].
Duplex real-time PCR was carried out with an initial RT
step at 50°C for 20 min, followed by PCR activation at 95°
C for 15 min and 50 cycles of amplification (95°C for 5 s,
55°C for 20 s, 72°C for 30 s). Fluorescence development
was measured once each cycle after the elongation step.
ResPlex III
An aliquot of the viral RNA which was used for in-house
RT-PCR was shipped on dry ice to Novartis, Marburg,
Germany. RT-PCR was performed using the OneStep RT-
PCR Kit (Qiagen, Hilden, Germany). The reaction mixture
included 5 μL of nucleic acids, 10 μL of 5x Qiagen
OneStep RT-PCR buffer, 2 μL of dNTP mix, 6 μL of
ResPlex III primer mix, 2 μL of Qiagen OneStep RT-PCR
enzyme mix, and 25 μL of RNase-free water. Amplification
was performed on a Mastercycler ep gradient S thermo-
cycler (Eppendorf, Hamburg, Germany), with the ramp rate
set to 15%. RT-PCR was carried out with an initial RT step
at 50°C for 30 min, followed by 15 min of PCR activation
at 95°C, 15 cycles of enrichment cycling (94°C for 30 s,
52°C for 1 min, 72°C for 1 min), six cycles of two-step
cycling (94°C for 15 s, 70°C for 1.5 min), and 30 cycles of
three-step cycling (94°C for 15 s, 52°C for 15 s, 72°C for
15 s). A final extension of 3 min at 72°C concluded the
amplification.
Following thermocycling, 5 μL of RT-PCR product, 10
μL of ResPlex III Bead Mix, and 35 μL of detection buffer
were incubated at 52°C for 10 min. For detection, 10 μL of
streptavidin–phycoerythrin conjugate mixed with detection
buffer were added. Mixtures were maintained at 52°C for
5 min, and then 120 μL of stopping buffer was added.
Samples were analyzed on a Luminex 200 system (Lumi-
nex, Austin, TX) running QIAplex MDD Software 1.1.15.
Raw mean fluorescence intensity data were exported to
Excel for storage and analysis. One negative control
(RNase-free water) and one independent positive control
were processed in parallel for each analysis.
Determining detection limits
Laboratory-grown influenza virus stocks of A/Bayern/7/95
(H1N1) and B/Baden Württemberg/3/06 with titers of 8.1
and 7.9 TCID50/mL, respectively, were diluted 10
8-fold in
ten-fold increments in virus transport medium. These serial
dilutions were used to establish the relationship between
influenza viral load determined by ResPlex III or by RRT-
PCR (i.e.,between TCID50/mL and viral cDNA copies),
since there is no international standard for influenza A and
B viral RNA. To determine TCID50, the influenza A and B
viruses were serially diluted ten-fold. Eight wells of a 96-
well plate containing a confluent monolayer of MDCK cells
(MDCK 33016 grown adherently) were inoculated with
0.1 mL of each dilution, and the cells were incubated at
37.0°C in a humidified atmosphere under 5.0% CO2. After
5 days, the cell cultures were examined microscopically for
CPE. The virus titer was calculated using the Spearman–
Karber method [8, 13].
Results
Demographics
Subjects were evenly split between genders (49% female, n=
222; 51% male, n=228). Since most of the referring doctors
were pediatricians, the majority of clinical isolates came
from children, although the subject ages ranged overall from
0 to 76.5 years (Fig. 1).
Sensitivity
For RRT-PCR, the detection limits were 2.1 and 2.9 log10
TCID50/mL for A/H1N1 and B, respectively. ResPlex III
showed higher sensitivity for the NS gene target than for
the HA gene (H1) or NA gene (N1). The detection limits
for the NS gene target were 1.1 and 1.9 log10 TCID50/mL
for A/H1N1 and B, respectively. Thus, ResPlex III was at
least one log more sensitive than in-house RRT-PCR.
Detection of type A and B viruses
Five assays were performed on each sample: ResPlex III,
RRT-PCR, rapid cell culture, conventional cell culture, and
a rapid diagnostic test (BD Directigen Flu A+B). ResPlex
III identified the greatest number of positive isolates (n=
261, or 58%). Thus, the sensitivity of ResPlex III was set at
Fig. 1 Age distribution of the subjects. Clinical specimens were
obtained from individuals aged 0 to 76.5 years. The median age was
6.8 years; the mean age was 11.3 years, with a standard deviation of
13.3 years
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100% and all other assays were calculated as a subset of that
total (Table 1). The sensitivity of RRT-PCR was 96%. Cell
culture techniques and the rapid test were far less sensitive
than molecular techniques, identifying 39% (BD Directigen
Flu A+B test) to 72% (rapid cell culture) of influenza-
positive specimens. One sample tested influenza A-positive
using the BD Directigen Flu A+B test and negative using all
other assays, suggesting a false-positive result.
One patient sample contained both A/H3N2 and B
viruses. Although the in-house RRT-PCR can distinguish
influenza A from influenza B, only the ResPlex III assay
was able to identify this dual infection and subtype at the
same time. Cell-based methods identified only the B virus,
and the BD rapid test produced a negative result.
Only nine samples were positive for influenza B virus in
this study (using ResPlex III). In this limited comparison, the
sensitivity of the other assays for detecting influenza B virus
appeared to be lower than the sensitivity for detecting
influenza A, and the molecular methods showed greater
sensitivity for detecting influenza B than the other methods.
The in-house RRT-PCRmethod detected 44% of samples that
were identified as influenza B-positive with ResPlex III.
Analysis of the cycle thresholds (Ct, the number of PCR
cycles required to amplify nucleic acid above background
levels) confirmed that ResPlex III was more sensitive than
RRT-PCR, particularly for the detection of influenza B virus.
Conventional cell culture and rapid culture detected only three
and one of these samples, respectively. No sample was
influenza B-positive with the BD Directigen Flu A+B test.
Sensitivity of cell culture and rapid diagnostic methods
in different age groups
Particularly in adults, the two cell culture methods and the rapid
test showed different sensitivities (Table 2). In one out of two
cases, influenza could be diagnosed in children using the BD
Directigen Flu A+B test. However, in this study, the
sensitivity of the rapid test dropped in specimens of adults
and the elderly to 14.3%. The same result was found using
rapid cell culture. Interestingly, the sensitivity of the conven-
tional cell culture method (virus isolation on MDCK cells)
remains unchanged (about 50%) in all of the age groups.
Typing efficiency of ResPlex III depends on viral load
The analysis of Ct values confirmed that ResPlex III was more
sensitive than the RRT-PCR, particularly for the B virus
(Table 3). The Ct value is the number of PCR cycles required
to amplify nucleic acid above background levels based on
the intensity of fluorescently labeled products. Therefore, a
higher Ct value indicates a lower starting quantity of nucleic
acid. In this study, there were several samples with very high
Ct values that had definitively positive ResPlex III results.
Also, ten samples (out of 261, or 3.85%) tested positive
using the ResPlex III assay but tested negative with RT-PCR.
These ten samples which were tested positive in ResPlex III
but tested negative in RRT-PCR were subjected to the
MDCK 33016PF suspension culture for virus isolation. Five
of the ten samples were tested positive after the second
passage in the hemagglutination assay, confirming that, for
these samples, the ResPlex III results were true-positive:
from one of three H3N2-positive and four of five B-positive
probes, influenza viruses were cultivated. In addition, one B-
positive material was also cultivated in adherent MDCK cells
and subtyped by the Robert Koch Institute (RKI).
Specificity of typing/subtyping by ResPlex III
HI assays were performed on 145 MDCK isolates to
determine the accuracy of ResPlex III subtyping (Table 4).
Table 1 Comparative sensitivity of various methods of influenza virus detectiona
ResPlex IIIb Real-time RT-PCR Rapid cell culture Conventional cell culture Quick test
n Sensitivity (%) n Sensitivity (%) n Sensitivity (%) n Sensitivity (%) n Sensitivity (%)
A/H3N2 203 100 200 98.5 157 77.3 117 57.6 87 42.9
A/H1N1 31 100 31 100.0 26 83.9 23 74.2 14 45.2
B 9 100 4 44.4 1 11.1 3 33.3 0 0
Untypedc 17 100 15 88.2 3 17.6 0 0 2d 11.8
Total positive 261 100 250 95.8 187 71.6 143 54.8 103 39.5
a Of these assays, only ResPlex III can distinguish influenza A subtypes (e.g., A/H1N1 and A/H3N2); the other assays can only distinguish
between influenza A and B. The types presented here were determined with ResPlex III, and all except two were confirmed by HI serotyping
b One sample did not have any usable material for the ResPlex III assay and one sample had a coinfection with A/H3N2 + B
cDefinition of untyped: only one component of the viral subtype was identified using ResPlex III (e.g., InfA [NS gene] and N1 [NA gene] were
positive, but all HA targets were negative)
d One sample was identified as influenza A by the quick test, but ResPlex III yielded a negative result
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In all, HI serotyping was accomplished on 135 (93%)
samples; 134 (99%) of these were identical to the subtypes
found with ResPlex III. Nine virus isolates could not be
further passaged or grew with too low HA titers, not
allowing HI testing. The one sample that was not identical
contained both A/H3N2 and B according to ResPlex III, but
only B was isolated in conventional cell culture and,
subsequently, also identified by HI. Thus, ResPlex III was
able to identify viral types/subtypes as accurately as HI
typing and subtyping of viruses isolated from PCR-positive
specimens. To further analyze samples that tested weakly
positive by ResPlex III and negative by RRT-PCR, Novartis
MDCK 33016PF suspension cells were used for influenza
virus recovery. Six out of these 11 specimens were positive
by hemagglutination assays after the first or second
passage. In conclusion, these weak-positive results obtained
by ResPlex III were correct and could be confirmed by
some positive virus isolations in the Novartis MDCK
33016PF suspension cell line.
Comparison to national and global surveillance data
Data from the WHO were collected from an online database
(FluNet) to determine the epidemiological data from Europe
[23]. National influenza surveillance in Germany is performed
by the Working Group on Influenza (“Arbeitsgemeinschaft
Influenza”, AGI) at the RKI [25]. Here, AGI data from
Germany [1] and WHO data from Europe (week 4 to week 14
of 2007) were compared with the results from this study.
The proportion of samples from patients with respiratory
symptoms that were positive for influenza virus varied from
23 to 58% in this study, depending on the assay used. Rates
of influenza virus detection were 58 and 56% for ResPlex
III and RRT-PCR, respectively, and were comparable to
data reported for national influenza surveillance by the AGI
and WHO that reported a detection rate of 53 and 25% for
the same time period and geographic region (Fig. 2a).
The influenza virus subtyping results obtained with
ResPlex III in the present study were also similar to the
data reported by the AGI and the WHO. During the 2006–
2007 influenza season, the National Influenza Reference
Center characterized 1,130 influenza virus isolates in
Germany and, according to the WHO data, 9,024 positive
samples were identified in Europe, of which 85% and 47%
were A/H3N2, 14% and 5% were A/H1N1, and 2% and 4%
were influenza B, respectively. The WHO also reported on
3,996 influenza A viruses, which were not subtyped,
accounting for 44% of all influenza-positive samples. In
this study, the relative proportions of these strains were
similar to data of the national influenza surveillance and the
European WHO data (Fig. 2b). ResPlex III identified 78%
of samples as containing A/H3N2, 12% as A/H1N1, 3% as
influenza B, 7% as untyped influenza A, and <1% as co-














53.6% 42.5% 42.1% 14.3%
Rapid cell culture 75.0% 77.2% 80.3% 47.6%
Virus isolation
(MDCK)
53.6% 59.8% 60.5% 57.1%
The 4 patients >60 years were all tested negative in all assays
Table 3 Sensitivity of ResPlex III compared with reverse transcriptase polymerase chain reaction (RT-PCR)
Qiagen ResPlex III resulta
Negative H1N1-positive H3N2-positive B-positive Untypedb positive
n (%) n (%) n (%) n (%) n (%)
RT-PCR Ct value Negative 189 42.1 0 3c 1.5 5d 55.6 2e 11.8
Weak positive (>30) 0 0 19 9.4 2 22.2 10 58.8
Moderate positive (>20 and ≤30) 0 17 54.8 96 47.3 2 22.2 5 29.4
Strong positive (≤20) 0 14 45.2 85 41.9 0 0
a Two samples were not included in this analysis: one sample had no material for ResPlex III and was RT-PCR-negative; another sample had a co-
infection of A/H3N2 + B tested in the ResPlex III assay and was positive in RT-PCR
bDefinition of untyped: at least one component of the viral subtype was identified using ResPlex III (e.g., InfA and N1 were positive but all HA
targets were negative)
c Samples subjected to virus isolation in MDCK 33016 PF suspension culture: 1/3 tested positive in the second passage
d Samples subjected to virus isolation in MDCK 33016 PF suspension culture: 4/5 tested positive in the second passage
e Samples subjected to virus isolation in MDCK 33016 PF suspension culture: 0/2 tested positive in the second passage
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infected with A/H3N2 and influenza B. Of the samples that
were untyped influenza A, all 17 were NS gene-positive,
but ten were negative for either the HA or NA genes and
seven were negative for both the HA and NA genes.
Discussion
Since only a vaccine whose virus strains match the
circulating influenza viruses will protect vaccinees effi-
ciently, frequent updating of the influenza vaccine compo-
sition is necessary. Therefore, the surveillance of influenza
virus strains that are circulating regionally and globally is
essential and requires highly sensitive and accurate diag-
nostic tests. Using isolates collected during the 2006–2007
influenza season, we have shown that ResPlex III can
detect and subtype strains of influenza A viruses with
adequate sensitivity and accuracy.
Influenza B viruses co-circulate along with influenza A
strains and cause epidemics in some years [6]. The
sensitivity of several diagnostic tests for detecting influenza
B virus has been shown to be less than for the influenza A
virus [7]. In this study, only nine influenza B virus
infections could be detected. Since there were relatively
few samples containing influenza B virus in this study, no
conclusion could to be drawn about a higher sensitivity of
ResPlex III compared to the other methods. However, the
sensitivity of the in-house real-time PCR was improved in
Table 4 Accuracy of ResPlex III subtyping compared with hemagglutination inhibition (HI) assays
ResPlex III resultsa
B A/H1N1 A/H3N2 A/H3N2 + B Untyped Negative
HI results B 3 – – 1 – –
A/H1N1 – 23 – – – –
A/H3N2 – – 109 – – –
A/H3N2 + B – – – – – –
Untyped – – 2b – – –
Negative – – 6d – 1c –
a Instances where the ResPlex III and HI results agree are highlighted in bold
b Because of low virus titers, two samples were unable to be subtyped by the HI assay
c Definition of untyped: only one component of the viral subtype was identified using ResPlex III (e.g., InfA and N1 were positive but all HA
targets were negative)
d No viruses were isolated from these six specimens. Thus, only polymerase chain reaction (PCR) analyses could be performed
Fig. 2 a Comparison of influenza-positive samples determined by
real-time reverse transcriptase polymerase chain reaction (RRT-PCR)
in this study to Arbeitsgemeinschaft Influenza (AGI) and World
Health Organization (WHO) data. The percentage of influenza-
positive samples obtained in this study was similar to those found
during the 2006–2007 season by local and regional influenza
surveillance systems (AGI in Germany and the WHO in Europe).
However, the greater sensitivity of molecular techniques may
contribute to the higher values seen for ResPlex III and RRT-PCR. b
Comparison of influenza virus subtyping results to the AGI and WHO
data. When influenza-positive samples are sorted according to
subtype, the relative proportion of each subtype is similar for ResPlex
III and the data from Europe (obtained by the WHO) and from
Germany (obtained by the AGI) (black = influenza B, gray =
influenza A, blue = A/H1N1, green = A/H3N2, red = A/H3N2 + B)
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further seasons after the QuantiTect RT mix from Qiagen
was replaced by the QuantiTect multiplex RT-PCR master
mix.
Among the analyzed samples, one sample contained
both A/H3N2 and B according to ResPlex III, but only B
was isolated in conventional cell culture and, subsequently,
also identified by HI. However, this difference is most
likely due to a limitation of cell-based assays: even when
multiple viral subtypes infect a cell, usually, only one
subtype persists and replicates [5, 17, 18].
In the present study, the sensitivities of conventional cell
culture, rapid culture, and quick test assays proved already
to be substantially lower than that of RRT-PCR and
ResPlex III. A study with specimens from adults and the
elderly would probably have yielded even lower sensitiv-
ities for these other detection methods. As shown in Table 3,
the positive detection rate of rapid cell culture and rapid test
(BD Directigen Flu A+B) was particularly high in
kindergarten and school-aged children. In this study,
clinical samples of children were overrepresented (Fig. 1),
because children aged <5 years have more influenza-related
medical care visits compared with older children, and,
particularly, those aged <2 years are at the greatest risk for
influenza-related hospitalizations [6, 14].
ResPlex III is an assay that is available as a customized
product for detecting and subtyping influenza virus in
clinical samples. Due to its multiplex format, ResPlex III
can detect more than one viral template in the same reaction
mixture, allowing viral co-infections to be identified in the
same specimen. In addition, ResPlex III as well other
specific molecular assays provide subtyping results within a
few hours compared with about one week required for cell
culture isolation and subsequent differentiation techniques.
However, the high sensitivity and subtyping accuracy of
ResPlex III that was demonstrated in this study should be
confirmed by analyzing more strains including H1N1
(2009) viruses collected from different seasons.
ResPlex III is able to detect subtypes with pandemic
potential (such as H2, H5, H7, and H9) that are not
normally screened in routine diagnostic procedures [24]. To
maintain the usefulness of the ResPlex III assay in
influenza surveillance, regular updates are important to
ensure that currently circulating influenza A subtypes as
well as other potentially harmful subtypes could be
detected. For example, the current ResPlex III panel could
be enhanced by the addition of the H4 and H6 subtypes,
which may have pandemic potential [20]. In general, this
technology allows the fast addition of new subtypes to the
panel. This was the case with the A/H1N1 (2009) strain,
which was implemented in only a few weeks in the ResPlex
II Plus Panel RUO [11], and, thus, the ResPlex III panel
should also be updated rapidly by including the specific
detection of the H1N1 (2009) virus.
In conclusion, the use of ResPlex III might potentially
translate into a quicker response to a potential pandemic
threat and provide timelier subtyping of circulating influ-
enza A strains during seasonal outbreaks. Thus, ResPlex III
has potential benefits for monitoring circulating influenza
viruses as a supplemental assay for influenza surveillance.
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